NASDAQ: CTNM
Contineum Therapeutics Inc Stock Ownership - Who owns Contineum Therapeutics?

Insider buying vs selling

Have Contineum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Daniel S. LorrainChief Scientific Officer2026-05-01300$13.84
$4.15kSell
Daniel S. LorrainChief Scientific Officer2026-05-013,870$13.06
$50.54kSell
Daniel S. LorrainChief Scientific Officer2026-04-064,170$13.43
$56.02kSell
Tim WatkinsCMO Head of Development2026-03-023,611$15.02
$54.22kSell
Daniel S. LorrainChief Scientific Officer2026-03-024,170$15.01
$62.58kSell
Tim WatkinsCMO Head of Development2026-03-023,611$4.50
$16.25kBuy
Carmine N. StengoneCEO and President2026-02-252,700$16.02
$43.24kSell
Daniel S. LorrainChief Scientific Officer2026-02-253,824$1.01
$3.86kBuy
Daniel S. LorrainChief Scientific Officer2026-02-253,824$16.01
$61.23kSell
Carmine N. StengoneCEO and President2026-02-252,700$1.26
$3.40kBuy

1 of 3

CTNM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CTNM insiders and whales buy or sell their stock.

CTNM Shareholders

What type of owners hold Contineum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Suvretta Capital Management LLC7.61%2,841,334$37.51MInstitution
Janus Henderson Group PLC6.56%2,448,979$32.33MInstitution
Ra Capital Management LP5.84%2,179,711$28.77MInstitution
Johnson Johnson5.30%1,979,173$26.13MInstitution
Johnson Johnson5.30%1,979,173$26.13MInsider
Franklin Resources Inc5.03%1,879,367$24.81MInstitution
Balyasny Asset Management LP4.94%1,842,800$24.32MInstitution
Perceptive Advisors LLC3.92%1,464,592$19.33MInstitution
Baker Bros Advisors LP3.81%1,420,838$18.76MInstitution
Vanguard Group Inc3.40%1,270,858$16.78MInstitution

1 of 3

CTNM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CTNM79.21%7.18%Net SellingNet Selling
XOMA19.42%80.58%Net SellingNet Buying
IMMX46.04%18.30%Net Buying
ZURA44.38%55.62%Net BuyingNet Buying
FULC70.01%29.99%Net Selling

Contineum Therapeutics Stock Ownership FAQ

Who owns Contineum Therapeutics?

Contineum Therapeutics (NASDAQ: CTNM) is owned by 79.21% institutional shareholders, 7.18% Contineum Therapeutics insiders, and 13.61% retail investors. Johnson Johnson is the largest individual Contineum Therapeutics shareholder, owning 1.98M shares representing 5.30% of the company. Johnson Johnson's Contineum Therapeutics shares are currently valued at $26.13M.

If you're new to stock investing, here's how to buy Contineum Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.